Cancer Letters
Volume 223, Issue 2 , Pages 227-237 , 8 June 2005

Synergistic interaction between platinum-based antitumor agents and demethylcantharidin

  • Kenneth K.W. To

      Affiliations

    • School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region, China
    • ,
  • Yee-Ping Ho

      Affiliations

    • School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region, China
    • Corresponding Author InformationCorresponding author. Tel.: +852 2609 6831; fax: +852 2603 5295.
    • ,
  • Steve C.F. Au-Yeung

      Affiliations

    • Department of Chemistry, Faculty of Science, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region, China

Received 26 August 2004 ,Revised 26 October 2004 ,Accepted 28 October 2004.

References 

  1. Giaccone G. Clinical perspectives on platinum resistance. Drugs. 2000;59:9–17
  2. Ho YP, Au-Yeung SCF, To KKW. Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med. Res. Rev. 2003;23:633–655
  3. Tashiro T, Kawada Y, Sakurai Y. Antitumor activity of a new platinum complex, oxalate(trans-l-1,2-diaminocyclohexane)platinum (II), new experimental data. Biomed. Pharmacother. 1989;43:251–260
  4. Rixe O, Ortuzar W, Alvarez M. Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem. Pharmacol. 1996;52:1855–1865
  5. Ho YP, To KKW, Au-Yeung SCF, Wang X, Lin G, Han X. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J. Med. Chem. 2001;44:2065–2068
  6. To KKW, Wang X, Yu CW, Ho YP, Au-Yeung SCF. Protein phosphatase 2A inhibition and circumvention of cisplatin cross-resistance by novel TCM-platinum anticancer agents containing demethylcantharidin. Bioorg. Med. Chem. 2004;12:4565–4573
  7. Li YM, Casida JE. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc. Natl Acad. Sci. USA. 1992;89:11867–11870
  8. Sodeoka M, Baba Y, Kobayashi S, Hirukawa N. Structure–activity relationship of cantharidin derivatives to protein phosphatases 1, 2A1, and 2B. Bioorg. Med. Chem. Lett. 1997;7:1833–1836
  9. Wang GS. Medical uses of Mylabris in ancient China and recent studies. J. Ethnopharmacol. 1989;26:147–162
  10. Barford D, Das AK, Egloff MP. The structure and mechanism of protein phosphatases: insights into catalysis and regulation. Annu. Rev. Biophys. Biomol. Struct. 1998;27:133–164
  11. Cohen P. The structure and regulation of protein phosphatases. Annu. Rev. Biochem. 1989;58:453–508
  12. Shenolinkar S, Nairn AC. Protein phosphatases: recent progress. Adv. Second Messenger Phosphoprotein Res. 1991;23:1–121
  13. McCluskey A, Sim ATR, Sakoff JA. Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J. Med. Chem. 2002;45:1151–1175
  14. To KKW, Ho YP, Au-Yeung SCF. Determination of the release of hydrolyzed demethylcantharidin from novel traditional Chinese medicine-platinum compounds with anticancer activity by gas chromatography. J. Chromatogr. A. 2002;947:319–326
  15. Ariza RR, Keyse SM, Moggs JG, Wood RD. Reversible protein phosphorylation modulates nucleotide excision repair of damaged DNA by human cell extracts. Nucleic Acids Res. 1996;24:433–440
  16. Engblom P, Rantanen V, Kulmala J, Helenius H, Grenman S. Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines. Br. J. Cancer. 1999;79:286–292
  17. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother. Pharmacol. 1998;41:385–390
  18. Li L, Keating MJ, Plunkett W, Yang LY. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol. Pharmacol. 1997;52:798–806
  19. Kogure T, Ueno Y, Iwasaki T, Shimosegawa T. The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother. Pharmacol. 2004;53:296–304
  20. Frost P, Abbruzzese JL, Hunt B, Lee D, Ellis N. Synergistic cytotoxicity using 2′-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. Cancer Res. 1990;50:4572–4577
  21. Lidor YJ, Shpall EJ, Peters WP, Bast RC. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int. J. Cancer. 1991;49:704–710
  22. Chou TC, Talalay P. Quantitative analysis of dose effect relationship: the combined effects of multiple drugs on enzyme inhibitors. In:  Wever G editors. Advances in Enzyme Regulation. New York: Pergamon Press; 1984;p. 27–55
  23. Chou TC, Talalay P. Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In:  Harrap KR,  Connors TA editor. New Avenues in Developments Cancer Chemotherapy. Bristol-Myers Symposium Series. New York: Academic Press; 1987;p. 37–64
  24. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J. Natl Cancer Inst. 1994;86:1517–1524
  25. Richon VM, Schulte N, Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res. 1987;47:2056–2061
  26. Lai SL, Hwang J, Perng RP, Whang-Peng J. Modulation of cisplatin resistance in acquired-resistant non-small cell lung cancer cells. Oncol. Res. 1995;7:31–38
  27. Mosmann T. Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;65:55–63
  28. Houchens DP, Ovejera AA. Experimental therapy in subcutaneous transplants. In:  Boven E,  Winograd B editor. The Nude Mice in Oncology Research. Boca Raton, FL: CRC Press; 1991;p. 134–147
  29. Matsumoto M, Takeda Y, Maki H, Hojo K, Wada T, Nishitani Y, et al. Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer. Jpn. J. Cancer Res. 2001;92:51–58
  30. Barret JM, Etievant C, Hill BT. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloids, in combination with other anticancer drugs. Cancer Chemother. Pharmacol. 2000;45:471–476
  31. Strandberg MC, Bresnick E, Eastman A. The significance of DNA cross-linking to cis-diamminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells. Chem. Biol. Interact. 1982;39:169–180
  32. Liu XH, Balzsek I, Comisso M, Legras S, Marion S, Quittet P, et al. Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells. Eur. J. Cancer. 1995;31:953–963
  33. Christian MC. Carboplatin. In:  DeVita V,  Hellman S,  Rosenberg SA editor. Cancer Principles and Practice of Oncology Update Series. vol. 3:New York, NY: Lippincott; 1989;p. 1–17

PII: S0304-3835(04)00850-X

doi: 10.1016/j.canlet.2004.10.036

Cancer Letters
Volume 223, Issue 2 , Pages 227-237 , 8 June 2005

Article Tools

* Image Usage & Resolution